Comparative Pharmacology
Head-to-head clinical analysis: MIRAPEX versus NEUPRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIRAPEX versus NEUPRO.
MIRAPEX vs NEUPRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dopamine receptor agonist (D3 > D2 > D4) with activity at α2-adrenergic and 5-HT1A receptors; increases dopamine receptor activation in striatum.
Rotigotine is a non-ergoline dopamine agonist with high affinity for dopamine D1, D2, D3, D4, and D5 receptors; also binds to serotonin 5-HT1A and alpha2-adrenergic receptors.
Initial: 0.375 mg orally once daily; titrate gradually based on efficacy and tolerability. Usual effective dose: 1.5-4.5 mg daily in 3 divided doses. Maximum dose: 4.5 mg/day.
Apply transdermally once daily; initial dose 2 mg/24h, titrated weekly by 2 mg/24h up to 6 mg/24h, maximum 8 mg/24h.
None Documented
None Documented
The terminal elimination half-life is 8–12 hours in healthy adults, allowing for three-times-daily dosing. In elderly patients, half-life may be prolonged to 12–14 hours due to age-related decline in renal function.
Single dose: 5-7 hours (transdermal); steady state: 7-10 hours; effective half-life for dosing is 8 hours due to reservoir in skin
Renal elimination accounts for approximately 90% of total clearance, with about 80% recovered as unchanged parent drug in urine. Biliary/fecal excretion is minimal (<10%).
Renal: 45% (metabolites), Fecal: 40% (metabolites), Biliary: 15%
Category C
Category C
Dopamine Agonist
Dopamine Agonist